Tao Xi
Second Military Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tao Xi.
Hepatology | 2010
Kui Wang; Jian Liu; Zhenlin Yan; Jun Li; Lehua Shi; Wen-Ming Cong; Yong Xia; Qifei Zou; Tao Xi; Feng Shen; Wang H; Mengchao Wu
The association between the overexpression of aspartyl‐(asparaginyl)‐β‐hydroxylase (AAH) and the invasiveness of hepatocellular carcinoma (HCC) in vitro has been reported. However, the prognostic value of AAH expression in HCC remains unclear. The purpose of this study was to investigate the relationship between AAH expression, tumor recurrence, and patient survival. We identified AAH as the most overexpressed gene in HCC by way of complementary DNA microarray hybridization. A prospective study of 233 patients undergoing curative resection indicated that AAH expression was an independent factor affecting recurrence (hazard ratio [HR] 3.161, 95% confidence interval [CI] 2.115‐4.724, P < 0.001) and survival (HR 2.712, 95% CI 1.734‐4.241, P < 0.001). Patients with AAH overexpression had a poorer prognosis than those with AAH underexpression (P < 0.001 for both recurrence and survival). In Barcelona Clinic Liver Cancer stage A patients with AAH overexpression or underexpression, the tumor recurrence and survival rates were also statistically different (45% and 85% versus16% and 33% in 1‐ and 3‐year cumulative recurrence rates, respectively; 73% and 37% versus 90% and 80% in 1‐ and 3‐year survival rates, respectively; P < 0.001 for both). Furthermore, in stage A patients with tumors measuring ≤5 cm in diameter, the time to recurrence was 26.7 ± 1.6 versus 51.9 ± 2.8 months, and the 1‐ and 3‐ year survival rates were 97% and 52% versus 100% and 90% in AAH overexpression and underexpression patients, respectively (P < 0.001 for both). Conclusion: AAH overexpression in HCC is strongly correlated with worse surgical outcome, and this molecule likely provides a more precise prognostic predictor in early stage HCCs. HEPATOLOGY 2010
Hepato-gastroenterology | 2012
Tao Xi; Lai Ec; Min Ar; Lehua Shi; Wu D; Xue F; Kui Wang; Zhenlin Yan; Yong Xia; Feng Shen; Lau Wy; Mengchao Wu
BACKGROUND/AIMS Prevention of recurrence is the most important strategy to improve long-term survival after resection of hepatocellular carcinoma (HCC). This comparative study aimed to evaluate the outcome of adjuvant transarterial chemoembolization (TACE) after hepatectomy. METHODOLOGY From February 1996 and September 2001, 721 consecutive patients (adjuvant TACE treatment vs. control group; 145 vs. 576) with R0 resection for HCC were analyzed. The prospective data was analyzed retrospectively. RESULTS After a median follow-up of 75 months, 89 patients (61.4%) in the adjuvant TACE group and 355 patients (61.6%) in the control group had recurrent disease. There was no significant difference in the tumor recurrence rate between the 2 groups. There was significant difference in the tumor recurrence time between the 2 groups. The 1-, 3- and 5-year overall survival rates were 96.5%, 70.0% and 55.9%, respectively, for the adjuvant TACE group and 80.8%, 49.7% and 38.8%, respectively, for the control group. The 1-, 3- and 5-year disease-free survival rates were 79.9%, 54.9% and 48.4%, respectively, for the adjuvant TACE group and 60.2%, 39.8% and 31.5%, respectively, for the control group. The differences in the disease-free survival rates and the overall survival rates between the 2 groups were significant. In subgroup analysis, there was significant survival benefit in the adjuvant TACE group in the subgroup of patients with risk factors of recurrence - large tumor size, presence of satellite tumor nodules and narrow resection margin. CONCLUSIONS Adjuvant TACE improved surgical outcome in those patients with risk factors of HCC recurrence.
Annals of Surgical Oncology | 2010
Yong Xia; Yinghe Qiu; Jun Li; Lehua Shi; Kui Wang; Tao Xi; Feng Shen; Zhenlin Yan; Mengchao Wu
Journal of Cancer Research and Clinical Oncology | 2011
Xin-Yuan Lu; Tao Xi; Wan-Yee Lau; Hui Dong; Zhi-Hong Xian; Hua Yu; Zhen Zhu; Feng Shen; Mengchao Wu; Wen-Ming Cong
Annals of Surgical Oncology | 2011
Xin-Yuan Lu; Tao Xi; Wan-Yee Lau; Hui Dong; Zhen Zhu; Feng Shen; Mengchao Wu; Wen-Ming Cong
World Journal of Gastroenterology | 2008
Meng Wang; Feng Shen; Lehua Shi; Tao Xi; Xi-feng Li; Xu Chen; Mengchao Wu
Chinese journal of surgery | 2007
Tao Xi; Yan Zl; Wang K; Li J; Xia Y; Shen F; Wu Mc
Hepato-gastroenterology | 2012
Yong Xia; Zhenlin Yan; Tao Xi; Kui Wang; Jun Li; Lehua Shi; Mengchao Wu; Feng Shen
Archive | 2011
Feng Shen; Yong Xia; Tao Xi
Archive | 2012
Yong Xia; Tao Xi; Feng Shen